

Contact Information

Name: Dr Andrew Ddungu Kambugu
Address: Physical Address: Room 155 Ground Floor, IDI Building Mulago Hospital Complex
Postal Address: P. O. Box 22418 Kampala, Uganda
Telephone: +256312307227 (Work)
Cell Phone: +256772507636
Email addresses: akambugu@idi.co.ug adkambugu@gmail.com

Other Personal Information

Date of Birth: 22 February 1973
Citizenship: Ugandan
Marital Status: Married (With two children)

Education

Academic Degrees

1992-1997 Bachelors of Medicine and Surgery (MB.ChB) Makerere University
1999-2002 Masters of Medicine (Internal Medicine) Makerere University

Additional Training

2002-2005 Fellowship, Infectious Diseases, Infectious Diseases Institute (IDI) /University of Utah/University of Manitoba. An experiential clinical mentorship that included the National Institutes of Health (NIH) K-30 clinical research course, at the University of Utah

2005 Summer Institute for Global Health, Canadian Coalition for Global Health Research, Ifakara, Tanzania. Research methods workshop for investigators from resource-limited settings

2007 Certificate, *Seven Habits of Highly Effective People* course by the Franklin Covey ® Company

2008 Certificate, *The 4 Disciplines of Execution* course by the Franklin Covey ® Company

2017 Certificate in *Leadership and Management in International Health* (LMIH) course, University of Washington 12-week modular course

Licensure and Professional Qualifications

1998 Uganda Medical and Dental Practitioners Council (UMDPC) #4107
2014 Fellow, Royal College of Physicians, London, UK

Employment History

Work History

Position: Executive Director

Period: May 2018 - present

Employer: Infectious Diseases Institute (IDI), Makerere University, Kampala, Uganda

Responsibilities: Overall oversight of all programmes at the Institute, including the Prevention Care and Treatment, Research, Training, Outreach and Global Health Security Programme. Oversight for the IDI Core Laboratory, which is fully under the management of the Institute.

Position: Head of Research Programme

Period: May 2012 - present

Employer: Infectious Diseases Institute (IDI), Makerere University, Kampala, Uganda

Responsibilities: Determining strategic direction of the research programme, oversight of all IDI research activities, management of the research programme budget and supervisor of 5 unit heads. Project management for specific research grants. Contribution to institutional strategy development as part of the senior management team.

Position: Head of Prevention Care and Treatment (PCT) Programme

Period: September 2005 – April 2012

Employer: Infectious Diseases Institute (IDI), Makerere University, Kampala, Uganda

Responsibilities: Oversight for IDI PCT programme, decentralization of clinical activities to Kampala city council clinics, development and implementation of clinic standard operating procedures, and development and implementation of care models for testing and adoption within wider IDI care activities. Project management of key PCT projects. Contribution to institutional strategy development as part of the senior management team.

Position: Infectious Diseases Fellow

Period: December 2002 – August 2005

Employer: Infectious Diseases Institute (IDI), Makerere University, Kampala, Uganda

Position: Attending Physician Ward 4B

Period: December 2002 – August 2005

Employer: Mulago National Referral and Teaching Hospital, Kampala, Uganda

Position: Senior House Officer (Medical Resident)

Period: October 1999-November 2002

Employer: Department of Medicine, Makerere University Medical School, Kampala, Uganda

Position: Medical Officer/Company Doctor

Period: November 1998- September 1999

Employer: Uganda Posts and Telecommunications Limited, Kampala, Uganda

Position: Junior House Officer (Intern Doctor)

Period: October 1997-September 1998

Employer: Mulago National Referral and Teaching Hospital, Kampala, Uganda



17/03/2021

Academic Positions

Position: Adjunct Associate Professor, Division of Infectious Diseases

Period: July 2013-Present

Institution: University of Minnesota, Minnesota USA

Position: Adjunct Assistant Professor, Division of Infectious Diseases

Period: June 2008-June 2013

Institution: University of Minnesota, Minnesota USA

Position: Honorary Senior Lecturer, Department of Medicine

Period: October 2012 - present

Institution: College of Health Sciences, Makerere University, Kampala Uganda

Governance Experience

2016-present Vice President, Researchers for Global Health (R4GH), a Swiss-Uganda entity with a 4-member advisory board

2012-present President, Uganda Society for Health Scientists (USHS), Chair of executive committee under a 2-member board

Research Experience

Current Research Grants

2017-present: The Fractional Dose Yellow Fever Vaccine Study: A 2-year US CDC funded study. \$ 500,000 per year budget. Role: Principal Investigator

2014-present: The Sharing HIV/AIDS Responsibilities (SHARE) Grant; A 5-year US CDC-funded implementation science study (Public Health Evaluation): \$450,000 per year budget Role: Principal Investigator.

2015-present The Game Changers Study: A 3-year behavioral Science study. \$200,000 per year budget. Role: Ugandan Principal Investigator

2015-present U54 HIV and Malignancies in Africa. 5-Year NIH Research Training Grant. Co-PI with J Martin (University of California, San Francisco): \$200,000 per year budget. Role: Ugandan lead on capacity building

2015-present D43 HIV and Co-Infections Grants. 5-year NIH research capacity building Grant. Co-Principal Investigator with Y Manabe (Johns Hopkins University): \$200,000 per year budget. Role: Ugandan lead on capacity building

Completed Research Grants

2015 Innovative Demand-generation for Voluntary Medical Circumcision; Funder: Bill and Melinda Gates Foundation; Role: Principal Investigator

2014 The Europe Africa Research Network on Second-line Antiretroviral Treatment (EARNST) Funder: EDCTP/MRC; Role IDI Principal Investigator

2010 The Development of Antiretroviral Therapy in Africa (DART); Funder Medical Research Council (MRC) Role: Investigator

Full Peer-Reviewed Publication List

1. Okoboi S, Twimukye A, Lazarus O, Castelnovo B, Agaba C, Immaculate M, Nanfuka M, **Kambugu A**, King R. Acceptability, perceived reliability and challenges associated with distributing HIV self-test kits to young MSM in Uganda: a qualitative study. *J Int AIDS Soc*. 2019 Mar;22(3):e25269
2. Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, **Kambugu A**, Castelnovo B, Lamorde M, Denti P. Low anti-tuberculosis drug concentrations in HIV-Tuberculosis co-infected adults with low body weight; is it time to update dosing guidelines? *Antimicrob Agents Chemother*. 2019 Mar 25. pii: AAC.02174-18
3. Kiragga AN, Mubiru F, Kambugu AD, Kanya MR, Castelnovo B. A decade of antiretroviral therapy in Uganda: what are the emerging causes of death? *BMC Infect Dis*. 2019 Jan 21;19(1):77.
4. Okoboi S, Castelnovo B, Moore DM, Musaazi J, **Kambugu A**, Birungi J, Nanfuka M, Van Rie A. Incidence rate of sexually transmitted infections among HIV infected patients on long-term ART in an urban and a rural clinic in Uganda. *BMC Public Health*. 2019 Jan 18;19(1):87.
5. Venter WDF, **Kambugu A**, Chersich MF, Becker S, Hill A, Arulappan N, Moorhouse M, Majam M, Akpomiemie G, Sokhela S, Poongulali S, Feldman C, Duncombe C, Ripin DHB, Vos A, Kumarasamy N. Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. *J Acquir Immune Defic Syndr*. 2019 Feb 1;80(2):224-233
6. Baumann A, Musaazi J, **Kambugu A**, Kälin M, Weissberg D, Ssemwanga D, Fehr J, Castelnovo B, Sekaggya-Wiltshire C, von Braun A. Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options. *J Acquir Immune Defic Syndr*. 2019 Apr 1;80(4):481-487.
7. Vos AG, Chersich MF, Klipstein-Grobusch K, Zuithoff P, Moorhouse MA, Lalla-Edward ST, **Kambugu A**, Kumarasamy N, Grobbee DE, Barth RE, Venter WD. Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir. *Retrovirology*. 2018 Dec 14;15(1):77. doi: 10.1186/s12977-018-0460-z.
8. Bachmann N, von Braun A, Labhardt ND, Kadelka C, Günthard HF, Sekaggya-Wiltshire C, Castelnovo B, **Kambugu A**, Lejone TI, Böni J, Yerly S, Perreau M, Klimkait T, Kouyos RD, Fehr J; Swiss HIV Cohort Study. Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. *J Antimicrob Chemother*. 2019 Feb 1;74(2):468-472.
9. Venter WDF, **Kambugu A**, Chersich MF, Becker S, Hill A, Arulappan N, Moorhouse M, Majam M, Akpomiemie G, Sokhela S, Poongulali S, Feldman C, Duncombe C, Brown Ripin DH, Kumarasamy N. Efficacy and safety of tenofovir disoproxil fumarate versus low-dose stavudine over 96 weeks: a multi-country randomised, non-inferiority trial. *J Acquir Immune Defic Syndr*. 2018 Nov 12.
10. Weissberg D, Mubiru F, **Kambugu A**, Fehr J, Kiragga A, von Braun A, Baumann A, Kälin M, Sekaggya-Wiltshire C, Kanya M, Castelnovo B. Ten years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort. *PLoS One*. 2018 Nov 1;13(11):e0206796.
11. Okoboi S, Castelnovo B, Moore DM, Musaazi J, **Kambugu A**, Birungi J, Kaleebu P, Nanfuka M, Kanya MR, Van Rie A. Risky sexual behavior among patients on long-term antiretroviral therapy: a prospective cohort study in urban and rural Uganda. *AIDS Res Ther*. 2018 Oct 19;15(1):15.
12. von Braun A, Castelnovo B, Ledergerber B, Cusato J, Buzibye A, **Kambugu A**, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C. High efavirenz serum concentrations in

- TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. *J Antimicrob Chemother.* 2019 Jan 1;74(1):135-138
13. Kwizera R, Parkes-Ratanshi R, Page ID, Sekaggya-Wiltshire C, Musaazi J, Fehr J, Castelnovo B, Kambugu A, Denning DW. Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis. *BMC Pulm Med.* 2017 Nov 21;17(1):149.
 14. Epiu I, Wabule A, **Kambugu A**, Mayanja-Kizza H, Tindimwebwa JVB, Dubowitz G. Key bottlenecks to the provision of safe obstetric anaesthesia in low- income countries; a cross-sectional survey of 64 hospitals in Uganda. *BMC Pregnancy Childbirth.* 2017 Nov 17;17(1):387.
 15. Hakim JG, Thompson J, Kityo C, Hoppe A, **Kambugu A**, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. *Lancet Infect Dis.* 2017 Nov 3. pii: S1473-3099(17)30630-8.
 16. Linnemayr S, Huang H, Luoto J, **Kambugu A**, Thirumurthy H, Haberer JE, Wagner G, Mukasa B. Text Messaging for Improving Antiretroviral Therapy Adherence: No Effects After 1 Year in a Randomized Controlled Trial Among Adolescents and Young Adults. *Am J Public Health.* 2017 Dec;107(12):1944-1950.
 17. Sekaggya-Wiltshire C, Castelnovo B, von Braun A, Musaazi J, Muller D, Buzibye A, Gutteck U, Henning L, Ledergerber B, Corti N, Lamorde M, Fehr J, **Kambugu A**. Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. *BMJ Open.* 2017 Sep 18;7(9): e014679.
 18. Kwizera R, Akampurira A, Kandole TK, Nielsen K, **Kambugu A**, Meya DB, Boulware DR, Rhein J; ASTRO-CM Study Team Evaluation of trypan blue stain in a haemocytometer for rapid detection of cerebrospinal fluid sterility in HIV patients with cryptococcal meningitis. *BMC Microbiol.* 2017 Aug 22;17(1):182.
 19. Wanyama JN, Nabaggala MS, Wandera B, Kiragga AN, Castelnovo B, Mambule IK, Nakajubi J, **Kambugu AD**, Paton NI, Wanyenze RK, Colebunders R, Easterbrook P. Significant rates of risky sexual behaviours among HIV-infected patients failing first-line ART: A sub-study of the Europe-Africa Research Network for the Evaluation of Second-line Therapy trial. *Int J STD AIDS.* 2017 Jan 1:956462417724707.
 20. Musaazi J, Kiragga AN, Castelnovo B, **Kambugu A**, Bradley J, Rehman AM. Tuberculosis treatment success among rural and urban Ugandans living with HIV: a retrospective study. *Public Health Action.* 2017 Jun 21;7(2):100-109. doi: 10.5588/pha.16.0115.
 21. Wandera B, Tumwesigye NM, Nankabirwa JI, **Kambugu AD**, Mafigiri DK, Kapiga S, Sethi AK. Hazardous alcohol consumption is not associated with CD4+ T-cell count decline among PLHIV in Kampala Uganda: A prospective cohort study. *PLoS One.* 2017 Jun 30;12(6): e0180015.
 22. Montgomery MP, Nakasujja N, Morawski BM, Rajasingham R, Rhein J, Nalintya E, Williams DA, Huppler Hullsiek K, Kiragga A, Rolfes MA, Donahue Carlson R, Bahr NC, Birkenkamp KE, Manabe YC, Bohjanen PR, Kaplan JE, **Kambugu A**, Meya DB, Boulware DR; COAT and ORCAS Trial Teams. Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts. *BMC Neurol.* 2017 Jun 12;17(1):110.
 23. Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, **Kambugu A**, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugenyi P, Walker AS;

- Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. *Lancet HIV*. 2017 Aug;4(8): e341-e348.
24. Orikiiriza J, Nakawesi J, Kikaire B, Turitwenka D, Schlech W, **Kambugu A**, Lamorde M, Normark J, Hennessy M, Musiime V, Rujumba J, Ndeezi G, Tumwesigye NM, Doherty DG, Achan J Unmet needs persist in pediatric HIV programs: lessons from selected case studies in Uganda. *AIDS*. 2017 May 15;31(8):1196-1199.
25. Nakanjako D, Akena D, Kaye DK, Tumwine J, Okello E, Nakimuli A, **Kambugu A**, McCullough H, Mayanja-Kizza H, Kamya MR, Sewankambo NK. A need to accelerate health research productivity in an African University: the case of Makerere University College of Health Sciences. *Health Res Policy Syst*. 2017 Apr 21;15(1):33.
26. Bershetyn A, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, **Kambugu A**, Bukusi E, Hartogensis W, Glidden DV, Wools-Kaloustian K, Yiannoutsos C, Martin J, Geng EH; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium The Causal Effect of Tracing by Peer Health Workers on Return to Clinic Among Patients Who Were Lost to Follow-up From Antiretroviral Therapy in Eastern Africa: A "Natural Experiment" Arising From Surveillance of Lost Patients. *Clin Infect Dis*. 2017 Jun 1;64(11):1547-1554
27. Sekaggya-Wiltshire C, von Braun A, Scherrer AU, Manabe YC, Buzibye A, Muller D, Ledergerber B, Gutteck U, Corti N, **Kambugu A**, Byakika-Kibwika P, Lamorde M, Castelnovo B, Fehr J, Kamya MR. Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. *J Antimicrob Chemother*. 2017 Apr 1;72(4):1172-1177.
28. von Braun A, Sekaggya-Wiltshire C, Scherrer AU, Magambo B, **Kambugu A**, Fehr J, Castelnovo B. Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis. *AIDS Res Ther*. 2017 Jan 5;14(1):1
29. Mavoko HM, Nabasumba C, da Luz RI, Tinto H, D'Alessandro U, **Kambugu A**, Baraka V, Rosanas-Urgell A, Lutumba P, Van Geertruyden JP Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. *Lancet Glob Health*. 2017 Jan;5(1): e60-e68.
30. Acen EL, Worodria W, Mulamba P, **Kambugu A**, Erume J. The frequency distribution of vitamin D Receptor *foK I* gene polymorphism among Ugandan pulmonary TB patients. *F1000Res*. 2016 Jul 29;5.
31. Kuznik A, Iliyasu G, Habib AG, Musa BM, **Kambugu A**, Lamorde M. Initiation of antiretroviral therapy based on the 2015 WHO guidelines. *AIDS*. 2016 Nov 28;30(18):2865-2873.
32. Rachlis B, Bakoyannis G, Easterbrook P, Genberg B, Braithwaite RS, Cohen CR, Bukusi EA, **Kambugu A**, Bwana MB, Somi GR, Geng EH, Musick B, Yiannoutsos CT, Wools-Kaloustian K, Braitstein P. Facility-Level Factors Influencing Retention of Patients in HIV Care in East Africa. *PLoS One*. 2016 Aug 10;11(8): e0159994.
33. Semeere AS, Castelnovo B, Bbaale DS, Kiragga AN, Kigozi J, Muganzi AM, Coutinho AG, **Kambugu A**. Innovative Demand Creation for Voluntary Medical Male Circumcision Targeting a High Impact Male Population: A Pilot Study Engaging Pregnant Women at Antenatal Clinics in Kampala, Uganda. *J Acquir Immune Defic Syndr*. 2016 Aug 15;72 Suppl 4:S273-9

34. Castelnovo B, Kiragga A, Mubiru F, **Kambugu A**, Kanya M, Reynolds SJ. First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda. *J Int AIDS Soc.* 2016 Jun 17;19(1):20773
35. Sekaggya C, Nalwanga D, Von Braun A, Nakijoba R, **Kambugu A**, Fehr J, Lamorde M, Castelnovo B. Challenges in achieving a target international normalized ratio for deep vein thrombosis among HIV-infected patients with tuberculosis: a case series. *BMC Hematol.* 2016 Jun 4; 16:16.
36. Nakanjako D, Kiragga AN, Musick BS, Yiannoutsos CT, Wools-Kaloustian K, Diero L, Oyaro P, Lugina E, Ssali JC, **Kambugu A**, Easterbrook P. Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa. *AIDS.* 2016 Jul 31;30(12):1913-22.
37. Elul B, Wools-Kaloustian KK, Wu Y, Musick BS, Nuwagaba-Biribonwoha H, Nash D, Ayaya S, Bukusi E, Okong P, Otieno J, Wabwire D, **Kambugu A**, Yiannoutsos CT. Untangling the Relationship Between Antiretroviral Therapy Use and Incident Pregnancy: A Marginal Structural Model Analysis Using Data From 47,313 HIV-Positive Women in East Africa. *J Acquir Immune Defic Syndr.* 2016 Jul 1;72(3):324-32.
38. Alvarez E, Belloso WH, Boyd MA, Inkaya AÇ, Hsieh E, **Kambugu A**, Kaminski G, Martinez E, Stellbrink HJ, Walmsley S, Brown TT, Mallon PW. Which HIV patients should be screened for osteoporosis: an international perspective. *Curr Opin HIV AIDS.* 2016 May;11(3):268-76
39. Semeere A, Wenger M, Busakhala N, Buziba N, Bwana M, Muyindike W, Amerson E, Maurer T, McCalmont T, LeBoit P, Musick B, Yiannoutsos C, Lukande R, Castelnovo B, Laker-Oketta M, **Kambugu A**, Glidden D, Wools-Kaloustian K, Martin J. A prospective ascertainment of cancer incidence in sub-Saharan Africa: The case of Kaposi sarcoma. *Cancer Med.* 2016 May;5(5):914-28.
40. Geng EH, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, **Kambugu A**, Bukusi E, Wenger M, Neilands TB, Glidden DV, Wools-Kaloustian K, Yiannoutsos C, Martin J. Retention in Care and Patient-Reported Reasons for Undocumented Transfer or Stopping Care Among HIV-Infected Patients on Antiretroviral Therapy in Eastern Africa: Application of a Sampling-Based Approach. *Clin Infect Dis.* 2016 Apr 1;62(7):935-944.
41. Castelnovo B, Kiragga A, Musaazi J, Sempa J, Mubiru F, Wanyama J, Wandera B, Kanya MR, **Kambugu A**. Outcomes in a Cohort of Patients Started on Antiretroviral Treatment and Followed up for a Decade in an Urban Clinic in Uganda. *PLoS One.* 2015 Dec 7;10(12): e0142722.
42. **Kambugu A**, Thompson J, Hakim J, Tumukunde D, van Oosterhout JJ, Mwebaze R, Hoppe A, Abach J, Kwobah C, Arenas-Pinto A, Walker SA, Paton NI; EARNEST Trial Team. Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses from the EARNEST Trial. *J Acquir Immune Defic Syndr.* 2016 Apr 15;71(5):506-13.
43. Nakanjako D, Kiragga AN, Musick B, Yiannoutsos C, Wools-Kaloustian K, Diero L, Oyaro P, Lugina E, Ssali JC, **Kambugu A**, Easterbrook P. Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy (ART) within the leDEA-East Africa cohort. *AIDS.* 2016 Mar 8. [Epub ahead of print] PubMed PMID: 26959510.
44. Camlin CS, Neilands TB, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, **Kambugu A**, Bukusi EA, Glidden DV, Wools-Kaloustian KK, Wenger M, Geng EH; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-leDEA) Consortium. Patient-reported factors associated with reengagement among HIV-infected patients disengaged from care in East Africa. *AIDS.* 2016 Jan 28;30(3):495-502.

45. Alvarez E, Belloso WH, Boyd MA, Inkaya AÇ, Hsieh E, **Kambugu A**, Kaminski G, Martinez E, Stellbrink HJ, Walmsley S, Brown TT, Mallon PW. *Which HIV patients should be screened for osteoporosis: an international perspective*. Curr Opin HIV AIDS. 2016 Feb 18.
46. Elul B, Wools-Kaloustian KK, Wu Y, Musick BS, Nuwagaba-Biribonwoha H, Nash D, Ayaya S, Bukusi E, Okong P, Otieno J, Wabwire D, **Kambugu A**, Yiannoutsos CT. *Untangling the relationship between antiretroviral therapy use and incident pregnancy: A marginal structural model analysis using data from 47,313 HIV-positive women in East Africa*. J Acquir Immune Defic Syndr. 2016 Feb 19. [Epub ahead of print] PubMed PMID: 26910499.
47. Castelnuevo B, Kiragga A, Musaazi J, Sempa J, Mubiru F, Wanyama J, Wandera B, Kanya MR, **Kambugu A**. Outcomes in a Cohort of Patients Started on Antiretroviral Treatment and Followed up for a Decade in an Urban Clinic in Uganda. PLoS One. 2015 Dec 7;10(12): e0142722.
48. Castelnuevo B, Kiragga A, Mubiru F, **Kambugu A**, Reynolds S. Long Term Virological Outcomes of HIV Infected Patients on Antiretroviral Treatment in Uganda. Value Health. 2015 Nov;18(7):A577
49. Parkes-Ratanshi R, Achan B, Kwizera R, **Kambugu A**, Meya D, Denning DW. Cryptococcal disease and the burden of other fungal diseases in Uganda; Where are the knowledge gaps and how can we fill them? Mycoses. 2015 Oct;58 Suppl 5:85-93
50. Elliott A, Nerima B, Bagaya B, **Kambugu A**, Joloba M, Cose S, Pantaleo G, Yazdanbakhsh M, Mabey D, Dunne D, Moffett A, Rwakishaya EK, Kaleebu P, Mbidde EK. Capacity for science in sub-Saharan Africa. *Lancet*. 2015 Jun 20;385(9986):2435-7.
51. Geng EH, Odeny TA, Lyamuya RE, Nakiwogga-Muwanga A, Diero L, Bwana M, Muyindike W, Braitstein P, Somi GR, **Kambugu A**, Bukusi EA, Wenger M, Wools-Kaloustian KK, Glidden DV, Yiannoutsos CT, Martin J. Estimation of Mortality among HIV-infected people on antiretroviral therapy treatment in east Africa: a sampling based approach in an observational, multisite, cohort study. *Lancet HIV*. 2015 Mar 1;2(3): e107-e116.
52. Cox JA, Lukande RL, Kalungi S, Van Marck E, Lammens M, Van de Vijver K, **Kambugu A**, Nelson AM, Colebunders R, Manabe YC. Accuracy of Lipoarabinomannan and Xpert MTB/RIF Testing in Cerebrospinal Fluid to Diagnose Tuberculous Meningitis in an Autopsy Cohort of HIV-Infected Adults. *J Clin Microbiol*. 2015 Aug;53(8):2667-73. doi: 10.1128/JCM.00624-15. Epub 2015 Jun 10.
53. Wandera B, Tumwesigye NM, Nankabirwa JI, **Kambugu AD**, Parkes-Ratanshi R, Mafigiri DK, Kapiga S, Sethi AK. Alcohol Consumption among HIV-Infected Persons in a Large Urban HIV Clinic in Kampala Uganda: A Constellation of Harmful Behaviors. *PLoS One*. 2015 May 11;10(5): e0126236.
54. Cox JA, Lukande RL, Kalungi S, Van Marck E, Van de Vijver K, **Kambugu A**, Nelson AM, Colebunders R, Manabe YC. Is Urinary Lipoarabinomannan the Result of Renal Tuberculosis? Assessment of the Renal Histology in an Autopsy Cohort of Ugandan HIV-Infected Adults. *PLoS One*. 2015 Apr 21;10(4): e0123323.
55. Rana Y, Haberer J, Huang H, **Kambugu A**, Mukasa B, Thirumurthy H, Wabukala P, Wagner GJ, Linnemayr S. Short message service (SMS)-based intervention to improve

- treatment adherence among HIV-positive youth in Uganda: focus group findings. *PLoS One*. 2015 Apr 16;10(4): e0125187.
56. Geng EH, Neilands TB, Thiébaut R, Bwana MB, Nash D, Moore RD, Wood R, Zannou DM, Althoff KN, Lim PL, Nachega JB, Easterbrook PJ, **Kambugu A**, Little F, Nakigozi G, Nakanjako D, Kiggundu V, Ki Li PC, Bangsberg DR, Fox MP, Prozesky H, Hunt PW, Davies MA, Reynolds SJ, Egger M, Yiannoutsos CT, Vittinghoff EV, Deeks SG, Martin JN CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. *Int J Epidemiol*. 2015 Feb;44(1):251-63.
57. Laker-Oketta MO, Wenger M, Semeere A, Castelnuevo B, **Kambugu A**, Lukande R, Asirwa FC, Busakhala N, Buziba N, Diero L, Wools-Kaloustian K, Strother RM, Bwana M, Muyindike W, Amerson E, Mbidde E, Maurer T, Martin J. Task Shifting and Skin Punch for the Histologic Diagnosis of Kaposi's Sarcoma in Sub-Saharan Africa: A Public Health Solution to a Public Health Problem. *Oncology*. 2015;89(1):60-5. doi: 10.1159/000375165. Epub 2015 Feb 27.
58. Bahr NC, Rolfes MA, Musubire A, Nabeta H, Williams DA, Rhein J, **Kambugu A**, Meya DB, Boulware DR. Standardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings. *Open Forum Infect Dis*. 2014 Aug 25;1(2):
59. Meya DB, Okurut S, Zziwa G, Rolfes MA, Kelsey M, Cose S, Joloba M, Naluyima P, Palmer BE, **Kambugu A**, Mayanja-Kizza H, Bohjanen PR, Eller MA, Wahl SM, Boulware DR, Manabe YC, Janoff EN Cellular immune activation in cerebrospinal fluid from ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome. *J Infect Dis*. 2015 May 15;211(10):1597-606.
60. Nakanjako D, Ssinabulya I, Nabatanzi R, Bayigga L, Kiragga A, Joloba M, Kaleebu P, **Kambugu AD**, Kamya MR, Sekaly R, Elliott A, Mayanja-Kizza H. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. *Trop Med Int Health*. 2015 Mar;20(3):380-90.
61. Wiltshire CS, Lamorde M, Scherrer A, Musaazi J, Corti N, Allan B, Nakijoba R, Nalwanga D, Henning L, Von Braun A, Okware S, Castelnuevo B, **Kambugu A**, Fehr J. Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda. *J Int AIDS Soc*. 2014 Nov 2;17(4 Suppl 3):19585
62. Nakanjako D, Otiti-Sengeri J, Ssewanyana I, Nabatanzi R, Bayigga L, Kirimunda S, Joloba M, Manabe YC, **Kambugu A**, Colebunders R, Mayanja-Kizza H CD4 T-cell activation and reduced regulatory T-cell populations are associated with early development of cataracts among HIV-infected adults in Uganda. *Immunol Lett*. 2014 Apr 28. pii: S0165-2478(14)00080-7.
63. Ssinabulya I, Kayima J, Longenecker C, Luwedde M, Semitala F, **Kambugu A**, Ameda F, Bugeza S, McComsey G, Freers J, Nakanjako D Subclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda. *PLoS One*. 2014 Feb 28;9(2):e89537

64. Bayigga L, Nabatanzi R, Sekiziyivu PN, Mayanja-Kizza H, Kanya MR, **Kambugu A**, Olobo J, Kiragga A, Kirimunda S, Joloba M, Nakanjako D. High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort. *BMC Immunol.* 2014 Jan 31;15:2
65. IeDEA and ART Cohort Collaborations, Avila D, Althoff KN, Mugglin C, Wools-Kaloustian K, Koller M, Dabis F, Nash D, Gsponer T, Sungkanuparph S, McGowan C, May M, Cooper D, Chimbetete C, Wolff M, Collier A, McManus H, Davies MA, Costagliola D, Crabtree-Ramirez B, Chaiwarith R, Cescon A, Cornell M, Diero L, Phanuphak P, Sawadogo A, Ehmer J, Eholie SP, Li PC, Fox MP, Gandhi NR, González E, Lee CK, Hoffmann CJ, **Kambugu A**, Keiser O, Ditangco R, Prozesky H, Lampe F, Kumarasamy N, Kitahata M, Lugina E, Lyamuya R, Vonthanak S, Fink V, d'Arminio Monforte A, Luz PM, Chen YM, Minga A, Casabona J, Mwango A, Choi JY, Newell ML, Bukusi EA, Ngonyani K, Merati TP, Otieno J, Bosco MB, Phiri S, Ng OT, Anastos K, Rockstroh J, Santos I, Oka S, Somi G, Stephan C, Teira R, Wabwire D, Wandeler G, Boule A, Reiss P, Wood R, Chi BH, Williams C, Sterne JA, Egger M. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. *J Acquir Immune Defic Syndr.* 2014 Jan 1;65(1): e8-16. doi: 10.1097/QAI.0b013e3182a39979.
66. Kiragga AN, Castelnovo B, Musomba R, Levin J, **Kambugu A**, Manabe YC, Yiannoutsos CT, Kiwanuka N. Comparison of methods for correction of mortality estimates for loss to follow-up after ART initiation: a case of the Infectious Diseases Institute, Uganda. *PLoS One.* 2013 Dec 31;8(12):e83524
67. Katusiime C, Schlech WF 3rd, Parkes-Ratanshi R, Sempa J, **Kambugu A**. Characteristics of Sexually Transmitted Infections among High-Risk HIV-Positive Patients Attending an Urban Clinic in Uganda. *J Int Assoc Provid AIDS Care.* 2013 Oct 21.
68. Nakiwogga-Muwanga A, Alamo-Talisuna S, Musaaazi J, **Kambugu A**, Ssekawungu P, Katabira E, Colebunders R. Inadequate Monitoring in Advanced Stages of Disease with Lack of Supportive Counseling Increases Attrition among Patients on Antiretroviral Treatment at a Large Urban Clinic in Uganda. *J Int Assoc Provid AIDS Care.* 2013 Sep 30.
69. Nakiwogga-Muwanga A, Katabira E, Kiragga A, **Kambugu A**, Nakibuuka-Lubwama E, Manabe YC, Alamo ST, Colebunders R. Factors before enrolment are associated with being removed from a Pharmacy-only Refill Programme at a large urban HIV/AIDS clinic, Uganda. *Int J STD AIDS.* 2014 Feb;25(2):105-12.
70. Nakiwogga-Muwanga A, Katabira E, Sempa J, **Kambugu A**, Nakibuuka-Lubwama E, Lamorde M, Mawejje J, Colebunders R. A Pharmacy-Only Refill Program at a Large HIV Clinic in Uganda: Experience and Satisfaction of Patients. *J Int Assoc Provid AIDS Care.* 2014 May;13(3):264-8
71. Okumu G, Makobore P, Kaggwa S, **Kambugu A**, Galukande M. Effect of emergency major abdominal surgery on CD4 cell count among HIV positive patients in a sub-Saharan Africa tertiary hospital—a prospective study. *BMC Surg.* 2013 Feb 26;13:4.
72. Castelnovo B, Kiragga A, Afayo V, Ncube M, Orama R, Magero S, Okwi P, Manabe YC, **Kambugu A**. Implementation of provider-based electronic medical records and improvement of the quality of data in a large HIV program in Sub-Saharan Africa. *PLoS One.* 2012;7(12): e51631.
73. Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda. Reynolds SJ, Sendagire H, Newell K, Castelnovo B, Nankya I, Kanya M, Quinn TC, Manabe YC, **Kambugu A**. *BMC Infect Dis.* 2012 Dec 27;12:381. doi: 10.1186/1471-2334-12-381.

74. Neema S, Atuyambe LM, Otolok-Tanga E, Twijukye C, **Kambugu A**, Thayer L, McAdam K Using a clinic based creativity initiative to reduce HIV related stigma at the Infectious Diseases Institute, Mulago National Referral Hospital, Uganda.. *Afr Health Sci*. 2012 Jun;12(2):231-9.
75. Wiesner DL, Moskalenko O, Corcoran JM, McDonald T, Rolfes MA, Meya DB, Kajumbula H, **Kambugu A**, Bohjanen PR, Knight JF, Boulware DR, Nielsen K. Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis. *MBio*. 2012 Sep 25;3(5). pii: e00196-12.
76. Sendagire I, Cobelens F, **Kambugu A**, Konde-Lule J, van der Loeff MS. Frequency and predictors for late start of antiretroviral therapy in primary care clinics, Kampala, Uganda. *J Acquir Immune Defic Syndr*. 2012 Nov 1;61(3): e33-9.
77. Semeere AS, Nakanjako D, Ddungu H, **Kambugu A**, Manabe YC, Colebunders R. Sub-optimal vitamin B-12 levels among ART-naïve HIV-positive individuals in an urban cohort in Uganda. *PLoS One*. 2012;7(7): e40072. doi: 10.1371/journal.pone.0040072. Epub 2012 Jul 2.
78. Katusiime C, **Kambugu A** rare entity of primary extranodal diffuse large B cell lymphoma of the lower limb calf in an HIV-infected young adult on highly active antiretroviral therapy. *BMJ Case Rep*. 2012 Mar 27;2012. pii: bcr1220115444.
79. Sendagire I, Schim Van der Loeff M, **Kambugu A**, Konde-Lule J, Cobelens F. Urban movement and alcohol intake strongly predict defaulting from tuberculosis treatment: an operational study. *PLoS One*. 2012;7(5): e35908. doi: 10.1371/journal.pone.0035908. Epub 2012 May 2.
80. Hermans SM, van Leth F, Manabe YC, Hoepelman AI, Lange JM, **Kambugu A** Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study. *HIV Med*. 2012 Jul;13(6):337-44.
81. Ataher Q, Portsmouth S, Napolitano LA, Eng S, Greenacre A, **Kambugu A**, Wood R, Badal-Faesen S, Tressler R The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa. *J Int AIDS Soc*. 2012 Jan 26;15(1):2.
82. Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, Musubire A, Lee SJ, **Kambugu A**, Janoff EN, Bohjanen PR. Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study. *PLoS Med*. 2010 Dec 21;7(12): e1000384.
83. Worodria W, Massinga-Loembe M, Mayanja-Kizza H, Namaganda J, **Kambugu A**, Manabe YC, Kestens L, Colebunders R. Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART. *Clin Dev Immunol*. 2011; 2011:758350.
84. Phipps W, Ssewankambo F, Nguyen H, Saracino M, Wald A, Corey L, Orem J, **Kambugu A**, Casper C. Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda. *PLoS One*. 2010 Nov 12;5(11): e13936.
85. Boulware DR, Meya DB, Bergemann TL, Williams D, Vlasova-St Louis IA, Rhein J, Staddon J, **Kambugu A**, Janoff EN, Bohjanen PR. Antiretroviral therapy down-regulates innate antiviral response genes in patients with AIDS in sub-saharan Africa. *J Acquir Immune Defic Syndr*. 2010 Dec 1;55(4):428-38.
86. Geng EH, Nash D, **Kambugu A**, Zhang Y, Braitstein P, Christopoulos KA, Muyindike W, Bwana MB, Yiannoutsos CT, Petersen ML, Martin JN. Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. *Curr HIV/AIDS Rep*. 2010 Nov;7(4):234-44.

87. Boulware DR, Bonham SC, Meya DB, Wiesner DL, Park GS, **Kambugu A**, Janoff EN, Bohjanen PR. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. *J Infect Dis*. 2010 Sep 15;202(6):962-70.
88. Meya DB, Manabe YC, Castelnovo B, Cook BA, Elbireer AM, **Kambugu A**, Kanya MR, Bohjanen PR, Boulware DR. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. *Clin Infect Dis*. 2010 Aug 15;51(4):448-55.
89. Hermans SM, Kiragga AN, Schaefer P, **Kambugu A**, Hoepelman AI, Manabe YC. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. *PLoS One*. 2010 May 7;5(5): e10527.
90. Babigumira JB, Castelnovo B, Lamorde M, **Kambugu A**, Stergachis A, Easterbrook P, Garrison LP. Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. *BMC Health Serv Res*. 2009 Oct 21;9:192
91. Katwere M, **Kambugu A**, Piloya T, Wong M, Hendel-Paterson B, Sande MA, Ronald A, Katabira E, Were EM, Menten J, Colebunders R. Clinical presentation and aetiologies of acute or complicated headache among HIV-seropositive patients in a Ugandan clinic. *J Int AIDS Soc*. 2009 Sep 19;12(1):21.
92. Shihab HM, Lutwama F, Piloya T, Castelnovo B, **Kambugu AD**, Colebunders R. Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause? *J Infect Dev Ctries*. 2009 Jun 1;3(5):405-7.
93. Weaver MR, Nakitto C, Schneider G, Kanya MR, **Kambugu A**, Lukwago R, Ronald A, McAdam K, Sande MA. Measuring the outcomes of a comprehensive HIV care course: pilot test at the Infectious Diseases Institute, Kampala, Uganda. *Acquir Immune Defic Syndr*. 2006 Nov 1;43(3):293-303.
94. **Kambugu A**, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, Kanya MR, Mayanja-Kizza H, Sande MA, Bohjanen PR, Boulware DR. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. *Clin Infect Dis*. 2008 Jun 1;46(11):1694-701.
95. Trachtenberg JD, **Kambugu AD**, McKellar M, Semitala F, Mayanja-Kizza H, Samore MH, Ronald A, Sande MA. The medical management of central nervous system infections in Uganda and the potential impact of an algorithm-based approach to improve outcomes. *Int J Infect Dis*. 2007 Nov;11(6):524-30. Epub 2007 May 18.
96. Hermans SM, Kiragga AN, Schaefer P, **Kambugu A**, Hoepelman AI, Manabe YC. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in Sub-Saharan Africa. *PLoS One*. 2010 May 7;5(5): e10527.
97. Babigumira JB, Castelnovo B, Lamorde M, **Kambugu A**, Stergachis A, Easterbrook P, Garrison LP. Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. *BMC Health Serv Res*. 2009 Oct 21; 9:192.
98. Castelnovo B, Manabe YC, Kiragga A, Kanya M, Easterbrook P, **Kambugu A**. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. *Clin Infect Dis*. 2009 Sep 15;49(6):965-72.
99. Castelnovo B, Kiragga A, Schaefer P, **Kambugu A**, Manabe Y. High rate of misclassification of treatment failure based on WHO immunological criteria. *AIDS*. 2009 Jun 19;23(10):1295-6;
100. Torok ME, **Kambugu A**, Wright E. Immune reconstitution disease of the central nervous system. *Curr Opin HIV AIDS*. 2008 Jul;3(4):438-45.

101. Meya D, Spacek LA, Tibenderana H, John L, Namugga I, Magero S, Dewar R, Quinn TC, Colebunders R, **Kambugu A**, Reynolds SJ. Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria. *J Int AIDS Soc.* 2009 Mar 4;12(1):3
102. Kiragga AK, Ocama P, Reynolds SJ, **Kambugu A**, Ojiambo H, Castelnuevo B. Validation of a portable hand-held lactate analyzer for determination of blood lactate in patients on antiretroviral therapy in Uganda. *J Acquir Immune Defic Syndr.* 2008 Dec 15;49(5):564-6.
103. Reid A, Stöhr W, Walker AS, Williams IG, Kityo C, Hughes P, **Kambugu A**, Gilks CF, Mugenyi P, Munderi P, Hakim J, Gibb DM; Development of Antiretroviral Therapy Trial. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. *Clin Infect Dis.* 2008 Apr 15;46(8):1271-81.
104. Waters L, **Kambugu A**, Tibenderana H, Meya D, John L, Mandalia S, Nabankema M, Namugga I, Quinn TC, Gazzard B, Reynolds SJ, Nelson M. Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda. *J Acquir Immune Defic Syndr.* 2007 Dec 15;46(5):590-3.
105. Kanya MR, Mayanja-Kizza H, **Kambugu A**, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuevo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A; Academic Alliance for AIDS Care and Prevention in Africa. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2007 Oct 1;46(2):187-93.
106. Songa PM, Castelnuevo B, Mugasha EB, Ocama P, **Kambugu A**. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). *Clin Infect Dis.* 2007 Aug 15;45(4):514-7.

Book Chapters

- 2009 *An Algorithmic Approach to the Diagnosis and Management of Headache and visual Loss in people living with HIV.* From the Ground up: Building Comprehensive HIV/AIDS Care Programs in resource-limited Settings. Volume 2: Pages 243-264.
- 2013 *Principles of Medicine in Africa.* Fourth Edition; Editors: D Mabey, G Gill, E Parry, W Weber and CJM Whitty. Chapter 17: HIV/AIDS Pages 195-231

Research Committee Roles

- 2018 to date Member Editorial Board, Journal of the Acquired Immune Deficiency Syndromes (JAIDS)
- 2017 to date Member, Guidelines and Economic Evaluation Group of the Centre for Global Development, Washington DC
- 2005- to Date Member, Scientific Review Committee (SRC) of the Infectious Diseases Institute
- 2017 to Date Member, Data Safety Monitoring Committee, AMBITION-CM Trial
- 2017 to Date Member, Data Safety and Monitoring Committee, *Call-for-life* Study
- 2016 to Date Member, Data Safety and Monitoring Committee, MRC Vaccine Trial
- 2012- 2015 Member, Data Safety and Monitoring Board, Cotrimoxazole Prophylaxis study MRC, Uganda
- 2008-2010 Member, End-points Review Committee for the PART TB study

Additional Research Roles

- 2017-present Member, Scientific Committee for the 2018 International AIDS Conference-TRACK B Clinical Science
- 2011-present President, Uganda Society for Health Scientists (USHS)
- 2015-present Member, Conference Scientific Committee, The UNESCO-Merck African Research Summit (MARS)
- 2014-present Member Conference Scientific Committee, International Workshop on HIV Treatment in Resource-Limited Settings (INTEREST)
- 2011 Program Abstract Review for Clinical tracts of the IAS Meeting in Rome 2011 and the ICASA 2011 meetings
- 2008-2011 Board Member, USHS
-

Training and Mentorship Roles

Supervised Dissertations

- 2009 *The influence of CD4 count on wound healing following emergency surgery.* Dr. Gabriel Okumu, 2009, M. Med (Surgery) Makerere University.
- 2009 *The etiologies of ulcerative sexually transmitted infections among HIV-outpatients attending the infectious Diseases clinic at IDI.* Dr. Edith Nyangoma, 2009 M. Med (Internal Medicine) Makerere University.
- 2010 *The effect of serum vitamin B 12 levels on CD4 recovery among individuals receiving anti-retroviral therapy at the infectious diseases clinic at IDI,* 2011. Dr. Aggrey Semeere, M. Med (Internal Medicine) Makerere University.

Mentored Research Capacity Development

- 2015 D43 on HIV and Liver Disease: 5-year NIH research capacity building Grant. Co-Investigator: Institutional (IDI) investigator
- 2015 NIH Forgarty Fellowship Program: Local faculty/mentor
- 2014: Global Fellowship Program, NIH/Foragarty grant. Local Mentor,
- 2013 Gilead Scholars Programme: for Masters. PhDs and Post Docs: Project Director

Clinical Care/Program Implementation & Committee Roles

- 2017-present Member, Third-line Antiretroviral Therapy sub-committee, Ministry of Health Uganda
- 2015- Present Project Steering Committee Member/Co-author: Emerging Infectious Diseases (EID) CDC-funded Grant
- 2007-to present Member, HIV Drug Resistance Monitoring Committee of the Ministry of Health, Uganda
-

- 2005-to present Member, Adult Antiretroviral Therapy (ART) sub-committee of the ART practice and implementation Guidelines Committee of the Ministry of Health (MOH), Uganda.
- 2010 Member, World Health Organization, Expert Consultation on Antiretroviral Therapy as Prevention
- 2007-2009 Project Director, Civil Society Fund (CSF) Grant for HIV Care

Awards/Honors

- 1992 Best Academic Performance in Physics Biology and Chemistry- Kings College Budo, Uganda
- 1991 Best Academic Performance in Physics Biology and Chemistry- Kings College Budo, Uganda
-
- 1992 Government of Uganda full scholarship for the Bachelors of Medicine and Bachelors of Surgery (MB.ChB) degree programme at Makerere University
- 1995 Common Wealth Universities Award for Best Medical student (pre-clinical stage) for the year 1995. The award included a 3-month elective attachment spent at The Chris-Hani Baragwaneth Hospital Johannesburg South Africa.
- 1999 The National Institutes of Health (NIH) Forgarty Program full sponsorship for the Masters in Medicine degree program at Makerere University
-
- 2001 The Guerrant International Travel Award of the Infectious Diseases Society of America (IDSA)
- 2014 Fellow, Royal College of Physicians, London, UK

Invited Lectures/Conference Session Chair Invitations

- 2018 Keynote Speaker HIV in Africa: Swiss Virology Conference/Workshop Grindelwald, Switzerland (scheduled for 19 January 2018)
- 2017 Chair, EDCTP/National Agency for AIDS Research (ANRS) symposium on HIV and Co-infections at the International AIDS Society (IAS) 2017 Meeting Paris, France
- 2016 Chair, Global HIV Clinical Forum on Integrase Inhibitors at the 21st International AIDS Conference in Durban South Africa.
- 2016 Invited Speaker, 90-90-90 Uganda Country Experience: Southern Africa HIV Clinician Society Annual Conference
- 2014 Chair, Plenary Session Day 2; Southern Africa HIV Clinician Society Annual Conference 2014
- 2013 What to consider when Initiating ART in Patients with HIV-associated Co-morbidities: Cryptococcal Meningitis and Tuberculosis Presentation: International AIDS Society Symposium, Kuala Lumpur, Malaysia
-

- 2013 Early Complications of Antiretroviral Therapy: The Immune Reconstitution Inflammatory Syndrome (IRIS) Perspectives from Resource-limited Settings, Exchange Visit Symposium: University of Zurich, Switzerland
- 2014 The Future of Antiretroviral Therapy in Africa: Leanings, Challenges and Ways Forward. *Trin Talks* Seminar, Trinity College Dublin, Ireland
- 2011 The Management of Central Nervous System Infections in the HAART era. The 13th International Workshop on HIV/AIDS for Resource Limited Settings (INTEREST), Dar-es salaam, Tanzania
- 2009 The Management of Immune Reconstitution Inflammatory Syndromes (IRIS) in patients on antiretroviral therapy; The IDI experience. The Inaugural Jim Muller Medical Symposium University of Kwazulu-Natal, South Africa
- 2008 The challenges of Managing HIV-Infected Individuals in Resource-limited Settings, Perspectives from the Uganda. Global Health Course. University of Minnesota, USA
- 2007 Update on the prevention and management of opportunistic infections. 1st International Workshop on Antiretroviral therapy in Resource-Limited Settings (INTEREST) Kampala, Uganda. -
- 2004 The indications for Anti-Retroviral Therapy in private practice. Lecture delivered to the Uganda Private Practitioners Association Annual meeting.

Participation in Scientific Conferences (Selected)

1. Conference on Retroviruses and Opportunistic Infections (CROI)- Considered to be the top HIV scientific meeting globally; 2005-2015 (10 consecutive years)
2. The International AIDS Conference: The number one global forum for scientists, clinicians, policy-makers and advocacy groups. For the Years 2006, 2010, 2012 and 2016.
3. The International AIDS Society IAS –Pathogenesis Meeting: For the Years 2015 and 2017
4. The South Africa HIV Clinicians Society SAHIV): For the Years 2014, and 2016
5. The International Workshop on HIV in resource Limited Settings (INTEREST): For the Years 2012, 2014, 2015, 2016
6. The Keystone TB HIV Meeting Kampala 2014

Professional Memberships

- 1998 Uganda Medical Association (UMA)
- 2001 Uganda Society of Health Scientists (USHS)
- 2003 Association of Physicians of Uganda (APU)
- 2005 Canadian Coalition for Global Health Research

2006 International AIDS Society

2016 Researchers for Global Health (R4GH)

Citizenship/Community Service

2010-2012 Patron, Young writers Club, Makerere University Medical School

2008-2011 Advisor, Youth Health Organization (YHO)

2003- to 2008 Board member, The SAS Foundation, Uganda: an international HIV Prevention Foundation

2004- to 2007 Regular Guest (weekly) on "Health net" Talk-show Radio One 90.0 FM, an educational program on HIV/AIDS issues.

2005- to 2006 Regular Guest (weekly) at the Central Broadcasting Services (CBS)98.2 FM "Esuubi mu bulamu" a Phone-in program, on HIV/AIDS issues.

2002-2003 Physician for "Never again" street children's program in Rubaga, Kampala.

1999 Mentor for orphaned children under the "Father's Heart" program of the Kampala Pentecostal Church.

General Interests

Swimming, Documentaries and Biographies, History of Science literature

Professional Referees:

1. Prof. Elly Katabira, FRCP

Professor of Medicine, School of Medicine

College of Health Sciences, Makerere University

P. O. Box 7072 Kampala Uganda

Past President, International AIDS Society

Phone: +256-41-530020 (Office) and +256 712 853 401 (Mobile)

E-mail: katabira@imul.com

2. Prof. Nicholas Paton, FRCP

Professor of Infectious Diseases, Department of Medicine


Senior Consultant, Division of Infectious Disease, University Medicine Cluster, National University Health System

National University of Singapore

Phone: +65 9187 1854

E-mail: mdcnijp@nus.edu.sg

Signed: _____



Date: 17th March 2021